Problem
People are living longer and want to have a high quality-of-life
.
.
Solution
Degenerative diseases are abnormalities in the body’s “repairing” or “regenerative” process. By activating and re-directing emphasis of the body’s normal reparative processes (which are controlled by stem cells and their related cytokines and growth factors), we can slow down the aging or degenerative process and restore or “supercharge” the body’s ability to repair / regenerate itself.
.
.
Our Mission
“Develop cellular therapies that add years to live and life to those years”
ADVANCED CELLULAR THERAPIES AND REGENERATIVE MEDICINE (ACTARM) is a biotech startup focused on developing advanced cellular therapies utilizing placental derived tissue (stem cells) as the cell source material. ACTARM plans to use epigenetics analysis and integrated analysis of multi—omics data to identify optimum cell source material. The goal of the company is to develop FDA approved “off-the-shelf” cellular therapies to treat various degenerative diseases, to delay aging, and to accelerate healing. ACTARM has developed and has patents filed on a novel advanced culturing platform and cell source harvesting and carrier system. ACTARM is not doing developmental research, but rather transitioning existing technologies to a new, advanced platform which will provide a more robust; higher fidelity cellular therapeutic product.
The stem cells utilized are placenta-derived, mesenchymal stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. These cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms.
ACTARM will initially focus on pre-clinical and clinical studies utilizing its novel stem cell based cellular therapeutic product (CTP) to treat athletic injuries and osteo-arthritic joint disorders as well as aesthetic related concerns such as skin rejuvenation, wound healing, and hair restoration. We will develop novel biomarkers to determine the optimal growth conditions for manufacturing CTPs. We will also develop new strategies and evaluate efficacy regarding cellular dosage, treatment regimens and deployment methods in our clinical trials. It is felt that these CPTS also have the potential to be used for a wide range of diseases, such as cardiovascular diseases, diabetes, acute lung injury, neurological disorders, transplant medicine, etc.
ACTARM will offer the most advanced cellular therapies for the treatment of musculoskeletal and joint athletic injuries, chronic joint injury and inflammation, and wound healing and tissue regeneration.
.
.
Product
ACTARM’s novel technology and procedures take advanced steps to preserve cell surface proteins and viability of tissue prior to culturing/processing. Our “cell source material” is closer to “embryonic” tissue state than other cell sources that are derived from umbilical cord or placental derived tissues, because of our processing techniques and procedures and our transport techniques and procedures.
.
.
Contact Us
